Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma

Carlos H Barrios¹
Daniel Herchenhorn²
Matías Chacón³
Paula Cabrera-Galeana⁴
Peter Sajben⁵
Ke Zhang⁶

¹Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil; ²Division of Clinical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil; ³Clinical Oncology, Alexander Fleming Institute, Buenos Aires, Argentina; ⁴Department of Medical Oncology, Instituto Nacional de Cancerología, México, Centro Oncológico Issemym Edomex, México; ⁵Pfizer Oncology, New York, NY, USA; ⁶Pfizer Oncology, La Jolla, CA, USA

Background: Sunitinib is an approved treatment for metastatic renal cell carcinoma (mRCC). The safety profile and efficacy of sunitinib were confirmed in a global expanded access trial (ClinicalTrials.gov identifier: NCT00130897). This report presents a subanalysis of the final trial data from patients in Latin America.

Methods: Treatment-naïve or previously treated mRCC patients aged ≥18 years received oral sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule. Treatment continued until disease progression, unacceptable toxicity, or withdrawal of consent. Safety was assessed regularly, and tumor measurements were scheduled per local practice (using Response Evaluation Criteria in Solid Tumors).

Results: In total, 348 patients from Latin America received sunitinib. Overall, 75% of patients had two or more sites of metastatic disease, 28% were aged ≥65 years, 14% had an Eastern Cooperative Oncology Group performance status ≥2, 9% had brain metastases, 9% had no prior nephrectomy, and 5% had non-clear cell RCC. Median treatment duration was 8 months, and median follow-up was 15.1 months. In total, 326 patients (94%) discontinued treatment, primarily due to death (41%) or lack of efficacy (22%). Most treatment-related adverse events were of mild to moderate severity (grade 1/2). Mucosal inflammation (reported in 54% of patients), diarrhea (53%), and asthenia (41%) were the most common any-grade treatment-related adverse events. Asthenia (12%), neutropenia (10%), and fatigue and thrombocytopenia (both 9%) were the most common grade 3/4 treatment-related adverse events. In total, 311 patients were included for tumor response, of whom eight (3%) had a complete response and 46 (15%) a partial response, yielding an objective response rate of 17%. Median duration of response, progression-free survival, and overall survival were 26.7, 12.1, and 16.9 months, respectively.

Conclusion: The efficacy and safety profile of sunitinib in patients with mRCC from Latin America was comparable to that in the entire cohort of the global expanded access trial.

Keywords: sunitinib, kidney cancer, expanded-access trial, Latin America, tyrosine kinase inhibitor

Introduction

Kidney cancer is the twelfth most common cancer worldwide, with an estimated 338,000 new diagnoses and 143,000 deaths in 2012.¹,² Most patients (~85%) diagnosed with kidney cancer have renal cell carcinoma (RCC) and approximately one-third will present with metastatic disease.³ Metastatic RCC (mRCC) is known to have a poor prognosis such that before the advent of targeted therapy that dramatically altered the therapeutic landscape, 5-year survival rates were <10%.⁴
Sunitinib malate is an oral, multitargeted inhibitor of vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and other receptor tyrosine kinases, approved worldwide for mRCC treatment. Prior to regulatory approval, a global expanded access trial of >4,500 patients confirmed the safety profile and efficacy of sunitinib in a broad population of patients who were ineligible for, or had no access to, sunitinib clinical trials.

A recent article by Goss et al highlighted that few clinical cancer trials are carried out in Latin America and that publication of epidemiological and trial data from the region is infrequent. Using the final trial data set, we report the safety and efficacy of sunitinib in mRCC patients in Latin American countries enrolled in the global expanded access trial; this is the first report from this region.

Patients and methods

Study population

Patients ≥18 years of age with histologically confirmed mRCC who were either treatment-naïve or previously treated and were ineligible to participate in the ongoing sunitinib clinical trials, but had investigator-determined potential to derive clinical benefit from sunitinib, were included in the study. Other inclusion criteria were resolution of acute toxicity arising from prior systemic therapy; radiotherapy or surgical procedure for mRCC to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 grade 1 or less; and adequate organ function. Exclusion criteria included prior treatment with sunitinib and diagnosis with any acute medical or psychiatric condition that, in the investigator’s judgment, would make inclusion inappropriate. More details on inclusion/exclusion criteria have been previously published.

Study design and treatment

This was a subanalysis of data from mRCC patients in Latin America (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Venezuela) enrolled in an international open-label, expanded access trial of sunitinib (SUTENT®; Pfizer Inc., New York, NY, USA) (ClinicalTrials.gov identifier: NCT00130897). The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was approved by the ethics committee at each center (Table S1). All patients provided written, informed consent. The primary objective was to provide access to sunitinib for patients who were ineligible for participation in, or had no access to, sunitinib clinical trials (in countries where regulatory approval had not yet been granted), but who had the potential to derive benefit, as judged by the investigator. Secondary objectives included assessment of safety and efficacy (objective response rate [ORR], progression-free survival [PFS], and overall survival [OS]).

Patients were enrolled between June 2005 and December 2007. Accrual of new patients was discontinued on a country-by-country basis according to treatment availability. All patients received oral sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule, in repeated 6-week cycles. Dose reductions to 37.5, 25, and then to 12.5 mg/day were permitted based on individual tolerance. In May 2006, a protocol amendment was implemented that gave the option of administering sunitinib on a continuous daily dosing schedule (usual starting dose 37.5 mg/day). Treatment continued until disease progression, unacceptable toxicity, or withdrawal of consent.

Study assessments

Evaluations performed at screening included assessment of disease and medical history, physical examination, biochemistry and hematology tests, and recording of concomitant medications. Safety data collection was mandatory and performed on days 1, 14, and 28 of the first cycle and on days 1 and 28 of subsequent cycles, until a protocol amendment (May 2006) removed the day 28 assessment in cycles ≥3. Safety assessments included physical examination, Eastern Cooperative Oncology Group performance status (ECOG PS), biochemistry and hematology tests, and 12-lead electrocardiogram. Adverse events (AEs) were graded according to NCI CTCAE version 3.0.

Tumor assessments were guided by the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0), but were not scheduled in the study protocol, and were performed according to the local standard of care, with response, PFS, and OS data collected when possible. ORR was defined as the proportion of patients with a complete or partial response according to RECIST. PFS was defined as the time from the start of treatment to disease progression or death due to any cause, whichever event occurred first. Only deaths that occurred within 28 days of the last dose were counted as PFS events; however, disease progression was not restricted to the treatment period plus the 28-day follow-up period. OS was defined as the time from start of therapy to death from any cause. Data on survival events were collected up to July 15, 2008. For patients who were not known to be dead at the time of analysis or the cut-off date, survival times were censored at the last follow-up.
Statistical analysis
As this was an expanded access trial, sample size was not predetermined; no inferential analyses were planned nor any hypotheses tested. All patients who received at least one dose of sunitinib comprised the intent-to-treat population for analyses. ORR was calculated with a corresponding 95% two-sided confidence interval (CI) using standard methods based on binomial distribution. Estimates of median PFS and OS with respective 95% CIs were determined using the Kaplan–Meier method.

Results
Patients
In total, 349 patients were enrolled in Latin America, of whom 348 received at least one dose of sunitinib and comprised the intent-to-treat population for analysis. Baseline characteristics are reported in Table 1.

Drug exposure
Details of sunitinib exposure and patient disposition are reported in Table 2. The median treatment duration was 8.0 months and median follow-up was 15.1 months. A total of 326 patients (94%) discontinued treatment, and dose reductions occurred in 168 patients (48%).

Safety
Most treatment-related AEs were of mild to moderate severity (grade 1/2; Table 3). Mucosal inflammation (54% of patients), diarrhea (53%), and asthenia (41%) were the most common any-grade treatment-related, nonhematologic AEs. The most frequently reported nonhematologic grade 3/4 AEs were asthenia (12%), fatigue (9%), diarrhea (8%), and hand–foot syndrome (7%). Rates of treatment-related cardiac failure or congestive cardiac failure of any grade were low (<1%). Neutropenia, thrombocytopenia, and anemia were the most common treatment-related hematologic AEs of any grade (28%, 26%, and 24%, respectively) and of grade 3/4 (10%, 9%, and 8%, respectively) (Table 3).

Efficacy
In total, 311 patients were included for tumor response (Table 4). Patients with non-RECIST tumor assessments were excluded from the analysis. Overall, ORR was 17%, and clinical benefit was reported in 57%. Median duration of response was 26.7 months (95% CI: 19.2–53.6) and median time to tumor progression was 15.7 months (95% CI: 13.0–18.1). ORR in patients with and without prior cytokine treatment was 19% and 15%, respectively, and that in subpopulations with poor prognostic features ranged from 7% to 17%.

Overall, median PFS was 12.1 months (95% CI: 10.6–14.0) (Figure 1), and median OS was 16.9 months (95% CI: 15.1–20.2) (Figure 2). Median PFS was 12.1 months (95% CI: 9.5–14.1) and 12.1 months (95% CI: 9.7–16.1) in patients with and without prior cytokine treatment, respectively. Median OS was 16.6 months (95% CI: 14.7–19.5) and 19.3 months (95% CI: 13.8–28.5) in patients with and without prior cytokine treatment, respectively.

Discussion
This subanalysis confirms the safety profile and efficacy of sunitinib in mRCC patients enrolled in Latin America as part...
of the global expanded access trial. Furthermore, the overall safety and efficacy profile was similar to that in the overall cohort,\(^1\) although some differences were noted.

A majority of the treatment-related AEs were mild to moderate (grade 1/2). The levels of common AEs such as mucosal inflammation (54%) and asthenia (41%) observed in this subanalysis were higher than those reported in the entire cohort (29% and 22%, respectively).\(^1\) Similarly, these AEs were more frequent in Spanish patients (48% and 68%, respectively),\(^1\) whereas Italian patients reported an elevated level of asthenia (44%) but not mucosal inflammation (29%).\(^1\) The incidence of mucosal inflammation in patients from the US (29%)\(^1\) was similar to that reported for the entire cohort. The incidence of common grade 3/4 AEs, namely asthenia (12%), neutropenia (10%), thrombocytopenia and fatigue (both 9%), and diarrhea and anemia (both 8%), were similar to that in the entire cohort, as well as the Spanish, Italian, and US subpopulations.\(^1\) Treatment discontinuation in the Latin American group was similar to that in the entire cohort (94% and 95%, respectively).\(^1\) Although the main reasons for discontinuation were the same, the numbers differed; 37% because of lack of efficacy and 21% because of death in the entire cohort\(^1\) compared with 22% and 41%, respectively, in the Latin American population. This reversal was also noted in the Spanish population (15% and 43%, respectively),\(^1\) but not in the Italian (46% and 17%, respectively)\(^1\), or US patients (32% and 19%, respectively).\(^1\) Whether these data reflect underlying ethnic differences, natural variation, or geographic-based differences in assessment and management remains to be determined.

The ORR in the Latin American population (17%) was similar to that seen in the overall cohort (16%).\(^1\) Of note, the ORR in patients with prior cytokine therapy was similar to that in patients with no prior cytokine therapy.
(19% versus 15%), suggesting a benefit even in patients previously treated with cytokines. Patients $>65$ years of age also achieved a similar ORR (17%) and had a clinical benefit rate of 49%. Latin America, like the rest of the world, is facing an aging population and the finding that older patients may also respond to sunitinib is worth noting. Interestingly, ORR was also similar in patients with non-clear cell RCC (17%), as was clinical benefit rate (56%). In addition, clinical benefit was observed in patients with other poor prognostic features, such as ECOG PS $\geq 2$ (24%) and brain metastases (38%).

Median PFS was slightly longer in the Latin American patients than in the overall cohort (12.1 and 9.4 months, respectively), but median OS was slightly shorter (16.9 and 18.7 months, respectively). This could potentially be explained by the limited treatment options available in the region after progression. The Latin American subgroup may have had a somewhat better prognosis than the overall cohort, having fewer patients classified as poor risk (7%) than in the overall cohort (26%).

Participation of Latin America in cancer clinical trials has been increasing in the past decade, but still remains low in comparison with that of North America or Europe. At the time of writing, there were 335 open cancer clinical trials registered in South America, 129 in Mexico, and 112 in Central America, whereas there were 7,431 in the US, 1,103 in Canada, and 4,798 in Europe (ClinicalTrials.gov, accessed July 28, 2015). Subanalyses of large global clinical trials such as this study provide an important opportunity to evaluate the regional outcomes and better understand the

| Parameters                      | All patients $^a$ (N=311) | Prior cytokines | Patient subgroups |
|--------------------------------|---------------------------|-----------------|------------------|
|                                | (n=188)                   | (n=123)         | (n=84)           | (n=42) | (n=18) | (n=29) |
| Number of evaluable patients   | 226 (73)                  | 140 (74)        | 86 (70)          | 51 (61) | 20 (48) | 14 (78) | 16 (55) |
| Objective response             | 54 (17)                   | 35 (19)         | 19 (15)          | 14 (17) | 4 (9)   | 3 (17)  | 2 (7)   |
| Complete response              | 8 (3)                     | 3 (2)           | 5 (4)            | 1 (1)   | 0       | 1 (6)   | 1 (3)   |
| Partial response               | 46 (15)                   | 32 (17)         | 14 (11)          | 13 (15) | 4 (9)   | 2 (11)  | 1 (3)   |
| Stable disease $\geq 3$ months | 124 (40)                  | 71 (38)         | 53 (43)          | 27 (32) | 6 (14)  | 7 (39)  | 9 (31)  |
| Progressive disease or stable  | 48 (15)                   | 34 (18)         | 14 (11)          | 10 (12) | 10 (24) | 4 (22)  | 5 (17)  |
| disease $<3$ months            |                           |                 |                  |         |         |         |         |
| Clinical benefit $^b$          | 178 (57)                  | 106 (56)        | 72 (59)          | 41 (49) | 10 (24) | 10 (56) | 11 (38) |

Notes: $^a$ Patients were excluded from the intent-to-treat population for objective response if they had non-RECIST tumor assessments. A further 85 patients were included in the analysis but were not assessed (n=38), not evaluable (n=1), or had missing data (n=46). $^b$ Clinical benefit = complete response + partial response + stable disease for $\geq 3$ months.

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; RECIST, Response Evaluation Criteria in Solid Tumors.

Figure 1 Kaplan–Meier estimate of PFS. Note: Patients were excluded from the intent-to-treat population for Kaplan–Meier estimate of PFS if they had non-RECIST tumor assessments. Abbreviations: CI, confidence interval; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

Figure 2 Kaplan–Meier estimate of OS. Abbreviations: CI, confidence interval; OS, overall survival.
potential regional specifics in areas where the available data are scant, such as Latin America.

The limitations of this expanded access study include the lack of a reference arm and an independent central review of tumor response. The tumor assessments were not mandated in the protocol and were performed according to the local standard of care, thus leading to missing data and a degree of variation in the findings.

In conclusion, these data confirm the safety and efficacy profile of sunitinib in a population of patients from Latin America with mRCC who encompassed a wide range of disease states, including poor prognosis of disease.

Acknowledgments
The authors would like to thank all the patients who participated in the trial and their families, as well as all trial investigators, research nurses, study coordinators, and operations staff. Medical writing support was provided by Andy Gannon and Jo Chapman at ACUMED®, an Ashfield company, part of UDG Healthcare plc (New York, NY, USA), with funding from Pfizer Inc. Editorial support was provided by Jaya Vas, PhD, of Engage Scientific Solutions, and was funded by Pfizer Inc.

Author contributions
CHB, DH, MC, and PC-G contributed to acquisition of data for this study. PS and KZ participated in supervision of this study. KZ contributed to the statistical analysis. All authors contributed to analysis and interpretation of the data, participated in developing the manuscript, read and approved the final draft, and take responsibility for the integrity of the data and the accuracy of the data analyses.

Disclosure
CHB has reported receiving consultant fees and research grants from Pfizer, Novartis, and Roche. PS and KZ are full-time employees of Pfizer with stock ownership. DH, MC, and PC-G report no conflicts of interest in this work.

References
1. World Cancer Research Fund International. Kidney cancer statistics [Internet]. Available from: http://www.wcrf.org/cancer_statistics/data_specific_cancers/kidney_cancer_statistics.php. Accessed July 25, 2014.
Supplementary material

Table S1 List of ethics committees or institutional review boards that approved this study

| Country | Ethics committee or institutional review board |
|---------|------------------------------------------------|
| Argentina | Comité Independiente de Ética para Ensayos en Farmacología Clínica Fundación de Estudios Farmacológicos y de Medicamentos (FEFYM)  
Comité de Ética de la Investigación del CEMIC  
Comité Docencia e Investigación – Hospital Frances  
Comité de Docencia e Investigación Instituto Alexander Fleming |
| Brazil | Comitê de Ética em Pesquisa da Armandade da Santa Casa de Misericórdia de Porto Alegre  
Comitê de Ética em Pesquisa da Pontificia Universidade Católica do Rio Grande do Sul – PUCRS  
Comitê de Ética em Pesquisa Fundação Antonio Prudente-Hospital A.C. Camargo-Hospital do Câncer  
Comitê de Ética em Pesquisa do Instituto Nacional de Câncer – INCA  
Comitê de Ética em Pesquisa do Hospital Israelita Albert Einstein  
Comitê de Ética em Pesquisa da Sociedade Beneficente de Senhores Hospital Sírio Libanês  
Comitê de Ética em Pesquisa da Fundação Mário Penna  
Comitê de Ética em Pesquisa Fundação Hospital Amaral Carvalho  
Comitê de Ética em Pesquisa da Maternidade Clímero de Oliveira – UFBA Complexo Hospitalar Universitário |
| Chile | Comité de Ética de Investigación Servicio de Salud Metropolitano Norte |
| Colombia | Comité Corporativo de Ética en Investigación de la Fundación Santa Fe de Bogotá  
Comité Corporativo de Ética en Investigación  
Comité de Ética e Investigación Biomédica, Fundación Clínica Valle de Lili Comité de Ética en Investigaciones |
| Ecuador | Universidad Central del Ecuador  
Comisión Nacional de Investigación Científica Instituto Mexicano del Seguro  
Comité de Bioética ISSSTEP  
Hospital Christus Muguender del Parque Comité de Ética |
| Mexico | Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Comité Institucional de Investigación Biomédica en Humanos  
Hospital Regional Mérida ISSSTE Comité de Investigación y Bioética  
Comité Científico de Bioética e Investigación del Centro Oncológico Estatal |
| Panama | Instituto Conmemorativo Gorgas |
| Peru | Comité de Ética de Investigación del HNGAI  
Comité de Ética del Hospital Nacional Edgardo Rebagliati Martins  
Centro Nacional de Bioética. CENABI |
| Venezuela | Comisión de Ética del Hospital Oncológico Padre Machado Hospital Oncológico Padre Machado |